TORVANTA
Other · S&P 500 · data as of 2026-10-05

AMRX stock analysis: AMRX

AMRX (AMRX) is an S&P 500 company in Other. It grades strongest on momentum and weakest on value.

The model's view of AMRX · subscribers

Where AMRX ranks among the 1,500 U.S. stocks the model scores each trading day, its expected return, the evidence for and against it, and whether the model portfolio holds it. The grades below describe the company's data; they are not the model's view.

See plans
What's happening with AMRX · updated 2026-10-05 · from prices and SEC filings

AMRX price performance

AMRX against the S&P 500, one year
+0%+50%+100%AMRX +106%S&P 500 +18%2025-09-292026-10-05
Year to date+61.5%S&P 500 +14.5% · ahead by 47.0 pts
1 year+95.9%S&P 500 +17.0% · ahead by 78.8 pts
3 years+421.8%S&P 500 +89.3% · ahead by 332.5 pts
5 years+274.8%S&P 500 +91.3% · ahead by 183.5 pts

Total returns with dividends reinvested.

AMRX factor grades

Each grade compares AMRX with the rest of its sector (A+ best, F worst); the numbers behind it are shown with the typical figure for its peers.

C-ValueP/E 41.5x (industry 20.1x)FCF yield 2.0% (industry 6.0%)
BGrowthRevenue growth +9% (industry +8%)
C+ProfitabilityOperating margin 14.6% (industry 9.6%)ROIC 18.3% (industry 10.1%)
AMomentum12-month change +96%From 52-wk high -1%

AMRX in plain numbers

AMRX key statistics

SectorOther
Industryn/a
IndexS&P 500
Market value$6.5B
Revenue growth (y/y)+9%
Free-cash-flow yield2.0%
Dividend yieldn/a
Next earnings (expected)2026-10-29
Valuation measures
Market value$6.5B
Enterprise value$8.9B
P/E (trailing)41.5x
Forward P/E (Torvanta estimate)27.7x
PEG (Torvanta estimate)0.55
Price / sales2.1x
Price / book196.8x
EV / revenue2.9x
EV / EBITDA19.7x
Financial highlights
Revenue, last 12 months$3.1B
Net income, last 12 months$157.4M
EPS, last 12 months (GAAP)$0.49
Gross margin39.3%
Operating margin14.6%
Net margin5.0%
Return on invested capital18.3%
Cash$127.6M
Total debt$2.6B
Debt / equity77.83x
Free cash flow, last 12 months$127.8M
Current ratio2.20x

Company figures from its latest SEC filings; market value and returns from end-of-day prices.

AMRX earnings trends

Revenue vs earnings
-$156K$203.5M$407.1M$610.7M$814.3MSep 2024 Revenue: $702.5MDec 2024 Revenue: $730.5MMar 2025 Revenue: $695.4MJun 2025 Revenue: $724.5MSep 2025 Revenue: $784.5MDec 2025 Revenue: $814.3MMar 2026 Revenue: $722.5MJun 2026 Revenue: $796.2MSep 2024 Net income: -$156KDec 2024 Net income: $11.9MMar 2025 Net income: $12.2MJun 2025 Net income: $22.4MSep 2025 Net income: $2.4MDec 2025 Net income: $35.1MMar 2026 Net income: $62.3MJun 2026 Net income: $57.7MSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Net margin: -0.0%Net margin: 1.6%Net margin: 1.8%Net margin: 3.1%Net margin: 0.3%Net margin: 4.3%Net margin: 8.6%Net margin: 7.2%-0%4%9%■ Revenue ■ Net income ━ Net margin
Earnings per share$-0.1$-0.0$0.1$0.1$0.2Sep 2024 EPS (GAAP, diluted): $0.0Dec 2024 EPS (GAAP, diluted): $-0.1Mar 2025 EPS (GAAP, diluted): $0.0Jun 2025 EPS (GAAP, diluted): $0.1Sep 2025 EPS (GAAP, diluted): $0.0Dec 2025 EPS (GAAP, diluted): $0.1Mar 2026 EPS (GAAP, diluted): $0.2Jun 2026 EPS (GAAP, diluted): $0.2Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026■ EPS (GAAP, diluted) Change from a year earlier: Mar 2026 +375% · Jun 2026 +157%

From the company's 10-Q and 10-K filings with the SEC.

AMRX financials (from SEC filings)

Fiscal yearFY2021FY2022FY2023FY2024FY2025
Revenue$2.1B$2.2B$2.4B$2.8B$3.0B
Net income$13.2M-$270.6M-$79.3M-$73.9M$72.1M
EPS (GAAP)$0.07$-0.86$-0.48$-0.38$0.23
Free cash flow$194.1M$18.7M$302.4M$243.2M$269.9M

AMRX earnings history

ReportedEPS (GAAP)EPS y/yRevenue y/yStock vs S&P 500, 2 days
2026-07-30$0.18+157%+10%-6.5%
2026-05-07$0.19+375%+4%-3.6%
2026-04-22$0.19+375%+4%-3.5%
2026-02-27$0.11n/a+11%-4.5%
2026-01-13$0.11n/a+11%+2.8%
2025-10-30$0.01n/a+12%+4.5%

About AMRX

Industry (SEC code)Pharmaceutical Preparations
Fiscal year endsDecember 31
Listed onNasdaq
FormerlyAtlas Holdings, Inc.

From the company's SEC registration record.

Companies similar to AMRX

CompanyMarket valueP/ERevenue growthOperating margin12-month change
AMRX AMRX$6.5B41.5x+9%14.6%+96%
HXL HXL$6.5Bn/a+5%11.5%+34%compare
TEX TEX$6.5B29.0x+29%5.7%+9%compare
ETSY ETSY$6.5B39.6x+1%16.0%-2%compare
MAC MAC$6.5Bn/a+1%n/a+31%
TXNM TXNM$6.5B44.3x+8%20.4%+6%
LNTH LNTH$6.5B24.3x+2%19.4%+86%

All Other stock ratings

Frequently asked questions

Is AMRX stock a buy?

Torvanta does not tell individuals what to buy. Its grades for AMRX are shown above. Subscribers see the model's rank, expected return and whether the model portfolio holds it. This is research, not a recommendation.

What is AMRX's P/E ratio?

AMRX trades at about 41.5 times its last 12 months of GAAP earnings reported to the SEC, and about 27.7 times Torvanta's own estimate of the next 12 months.

When does AMRX report earnings next?

Based on its filing history, Torvanta expects AMRX to report around 2026-10-29.

How has AMRX performed against the S&P 500?

Over the past year AMRX returned +95.9%, against +17.0% for the S&P 500, dividends reinvested.

See the model's view

Subscribers get the model's rank and expected return for every covered company, the reasoning behind each, and the Torvanta model portfolio's trades each trading day, sized and explained, at three risk levels.

See plans Or get the free weekly newsletter

Torvanta is research only - not investment advice and not a recommendation to buy or sell any security. Grades describe a company's reported data against its sector; they are not the model's view, change as data changes and can be wrong. Financial figures come from the company's SEC filings; returns include reinvested dividends. Past performance does not predict future results.

All stock ratings · Stock lists · AI stock research · Model portfolio · Research · Disclaimer